Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral administration
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2006 |
| gptkbp:ATCCode |
L01XE06
|
| gptkbp:brand |
gptkb:dasatinib
|
| gptkbp:CASNumber |
302962-49-8
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sprycel
|
| gptkbp:indication |
gptkb:Philadelphia_chromosome-positive_leukemia
|
| gptkbp:KEGGID |
D03665
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
2323130
3062316 CHEMBL1421 DB01254 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
QT prolongation
fluid retention myelosuppression |
| gptkbp:UNII |
4XF63H2V5Q
|
| gptkbp:usedFor |
gptkb:chronic_myeloid_leukemia
leukemia |
| gptkbp:bfsParent |
gptkb:Bristol_Myers_Squibb
gptkb:百时美施贵宝 gptkb:Bristol-Myers_Squibb |
| gptkbp:bfsLayer |
6
|